Neumora Therapeutics

(NASDAQ) NMRA

Current Price$2.25

Market Cap$422.01M

Since IPO (2023)-86%

5 YearN/A

1 Year+198%

1 Month+16%

Neumora Therapeutics Financials at a Glance

Market Cap

$422.01M

Revenue (TTM)

$0.00

Net Income (TTM)

$236.93M

EPS (TTM)

$-1.45

P/E Ratio

-1.59

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Price

$2.25

Volume

16,313

Open

$2.38

Price

$2.25

Volume

16,313

Open

$2.38

Previous Close

$2.31

Daily Range

$2.24 - $2.40

52-Week Range

$0.61 - $3.65

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Price

$2.25

Volume

16,313

Open

$2.38

Previous Close

$2.31

Daily Range

$2.24 - $2.40

52-Week Range

$0.61 - $3.65

NMRA News

Neumora (NMRA) Q2 Loss Improves 10%

Motley Fool Markets TeamAug 6, 2025

Why Shares of Neumora Therapeutics Slumped This Week

James HalleySep 21, 2023

NMRA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neumora Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Paul L. Berns

Website

www.neumoratx.com

Headquarters

Watertown, DE 02472, US

NMRA Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-121%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-62.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$422.01M

Shares Outstanding

182.69M

Volume

16.31K

Avg. Volume

1.42M

Financials (TTM)

Gross Profit

$5.00M

Operating Income

$241.16M

EBITDA

$233.37M

Operating Cash Flow

$206.44M

Capital Expenditure

$0.00

Free Cash Flow

$206.44M

Cash & ST Invst.

$182.53M

Total Debt

$477.00K

Neumora Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$422.01M

N/A

Market Cap/Employee

$3.84M

N/A

Employees

110

N/A

Net Income

$59.45M

-1.1%

EBITDA

$57.41M

+8.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$182.05M

-40.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$193.00K

N/A

Short Term Debt

$284.00K

-84.7%

Return on Assets

-1.24%

N/A

Return on Invested Capital

-1.52%

N/A

Free Cash Flow

$47.94M

+4.8%

Operating Cash Flow

$47.95M

+4.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AUTLAutolus Therapeutics plc

AUTLAutolus Therapeutics plc$1.63+3.50%

FULCFulcrum Therapeutics, Inc.

FULCFulcrum Therapeutics, Inc.$7.03+0.14%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$3.65-0.68%

FDMT4D Molecular Therapeutics, Inc.

FDMT4D Molecular Therapeutics, Inc.$9.65+2.22%

BCYCBicycle Therapeutics plc

BCYCBicycle Therapeutics plc$4.88-1.32%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$11.05+2.46%

LXRXLexicon Pharmaceuticals, Inc.

LXRXLexicon Pharmaceuticals, Inc.$1.63+1.64%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

DGXXDigi Power X

DGXXDigi Power X$5.37+0.36%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.05-0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.82+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$48.47-0.04%

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF$8.44-0.06%

BBBlackBerry

BBBlackBerry$5.50-0.01%

AALAmerican Airlines Group

AALAmerican Airlines Group$12.19+0.03%

Questions About NMRA

What is the current price of Neumora Therapeutics?

Neumora Therapeutics is trading at $2.25 per share.

What is the 52-week range for Neumora Therapeutics?

Over the past 52 weeks, Neumora Therapeutics has traded between $0.61 and $3.65.

How much debt does Neumora Therapeutics have?

As of the most recent reporting period, Neumora Therapeutics reported total debt of $55.01M.

How much cash does Neumora Therapeutics have on hand?

Neumora Therapeutics reported $182.53M in cash and cash equivalents in its most recent financial results.

What is Neumora Therapeutics’s dividend yield?

Neumora Therapeutics does not currently have a dividend yield.

Neumora Therapeutics

Neumora Therapeutics Financials at a Glance

NMRA News

Neumora (NMRA) Q2 Loss Improves 10%

Why Shares of Neumora Therapeutics Slumped This Week

NMRA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Neumora Therapeutics

NMRA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Neumora Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NMRA

What is the current price of Neumora Therapeutics?

What is the 52-week range for Neumora Therapeutics?

How much debt does Neumora Therapeutics have?

How much cash does Neumora Therapeutics have on hand?

What is Neumora Therapeutics’s dividend yield?

Premium Investing Services